NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT02506153 2026-03-18
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT01274338 2026-02-18
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01708941 2025-11-26
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03899987 2025-08-27
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
Phase 2 Active not recruiting